Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

Fig. 2

Log-rank testing in the chemotherapy group. Log-rank testing did not show statistically significant differences in median overall survival (OS) between single-agent therapy and carboplatin-based doublet therapy groups (a). To note, the OS of patients who received chemotherapy for only 1 cycle was significantly shorter than those of patients who received chemotherapy for ≥2 cycles (b)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us